Cargando…
Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patien...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/ https://www.ncbi.nlm.nih.gov/pubmed/35975116 http://dx.doi.org/10.18502/ijhoscr.v16i1.8435 |
_version_ | 1784760122272120832 |
---|---|
author | Shaiegan, Mojgan Moghaddam, Mostafa Maghsudlu, Mahtab Azarkeivan, Azita Zolfaghari, Sima Pourfatollah, Ali-Akbar Soleimanzadeh, Peyman Shahverdi, Ehsan |
author_facet | Shaiegan, Mojgan Moghaddam, Mostafa Maghsudlu, Mahtab Azarkeivan, Azita Zolfaghari, Sima Pourfatollah, Ali-Akbar Soleimanzadeh, Peyman Shahverdi, Ehsan |
author_sort | Shaiegan, Mojgan |
collection | PubMed |
description | Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion. |
format | Online Article Text |
id | pubmed-9339119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-93391192022-08-15 Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients Shaiegan, Mojgan Moghaddam, Mostafa Maghsudlu, Mahtab Azarkeivan, Azita Zolfaghari, Sima Pourfatollah, Ali-Akbar Soleimanzadeh, Peyman Shahverdi, Ehsan Int J Hematol Oncol Stem Cell Res Original Article Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2022-01-01 /pmc/articles/PMC9339119/ /pubmed/35975116 http://dx.doi.org/10.18502/ijhoscr.v16i1.8435 Text en Copyright © 2022 Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Original Article Shaiegan, Mojgan Moghaddam, Mostafa Maghsudlu, Mahtab Azarkeivan, Azita Zolfaghari, Sima Pourfatollah, Ali-Akbar Soleimanzadeh, Peyman Shahverdi, Ehsan Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title | Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title_full | Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title_fullStr | Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title_full_unstemmed | Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title_short | Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients |
title_sort | red blood cell immunization and contributing factors in 685 thalassemia patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/ https://www.ncbi.nlm.nih.gov/pubmed/35975116 http://dx.doi.org/10.18502/ijhoscr.v16i1.8435 |
work_keys_str_mv | AT shaieganmojgan redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT moghaddammostafa redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT maghsudlumahtab redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT azarkeivanazita redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT zolfagharisima redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT pourfatollahaliakbar redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT soleimanzadehpeyman redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients AT shahverdiehsan redbloodcellimmunizationandcontributingfactorsin685thalassemiapatients |